CADTH | Evidence Driven
CADTH | Evidence Driven

Revlimid for Multiple Myeloma - Details

Détails

Fichiers
Generic Name:
Lenalidomide
État du projet:
Terminé
Domaine thérapeutique:
Multiple Myeloma (as maintenance therapy)
Fabricant:
Celgene Inc.
Brand Name:
Revlimid
Gamme de produits:
Examen en vue du remboursement
Numéro de projet :
PC0029-000
Strength:
5mg, 10mg, 15mg and 25mg capsules
Tumour Type:
Myeloma
Indications:
Multiple Myeloma
Funding Request:
For the maintenance treatment of newly diagnosed multiple myeloma in patients after stem-cell transplantation
Review Status:
Complete
Pre Noc Submission:
Yes
Date NOC Issued:
Sponsor:
Celgene Inc.
Submission Date:
Submission Deemed Complete:
Priorisation demandée:
Non demandée
Stakeholder Input Deadline ‡:
Check-point meeting:
pERC Meeting:
Initial Recommendation Issued:
Feedback Deadline ‡:
Notification to Implement Issued:
Recommandation:
Remboursement sous critères cliniques ou conditions
pERC Meeting:
Final Recommendation Issued:

Fichiers

Provincial Funding Summary Résumé, financement provincial Afficher le PDF
Lenalidomide (Revlimid) for Multiple Myeloma - pERC Final Recommendation Recommandation finale 22 octobre 2013 Afficher le PDF
Lenalidomide (Revlimid) for Multiple Myeloma - Final Clinical Guidance Report Rapports d'orientation 22 octobre 2013 Afficher le PDF
Lenalidomide (Revlimid) for Multiple Myeloma - Final Economic Guidance Report Rapports d'orientation 22 octobre 2013 Afficher le PDF
Lenalidomide (Revlimid) for Multiple Myeloma - pERC Initial Recommendation Recommandation initiale 03 octobre 2013 Afficher le PDF
Lenalidomide (Revlimid) for Multiple Myeloma - PAG Feedback on Initial Recommendation Rétroaction 22 octobre 2013 Afficher le PDF
Lenalidomide (Revlimid) for Multiple Myeloma - Manufacturer (Celgene Inc.) Feedback on Initial Recommendation Rétroaction 22 octobre 2013 Afficher le PDF
Lenalidomide (Revlimid) for Multiple Myeloma - Patient Advocacy Group (Myeloma Canada) COI Declarations Rétroaction 22 octobre 2013 Afficher le PDF

‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.

Dernière mise à jour : 02 septembre 2016